Jonathan Gerber, MD from Levine Cancer Institute discusses hopeful for the FDA approval of the IDH1 inhibitor and new generation of inhibitors like FLT3 are hopefully more effective at the 2017 American Society of Hematology.
Hopeful for the FDA Approval of the IDH1 Inhibitor – New generation of inhibitors like FLT3 are hopefully more effective
By Editor